Have a feature idea you'd love to see implemented?
Let us know!
ATOS Atossa Therapeutics Inc
Price (delayed)
$1.19
Market cap
$149.7M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.22
Enterprise value
$74.83M
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and
Highlights
The net income has grown by 10% YoY but it has contracted by 3.9% from the previous quarter
The company's EPS rose by 8% YoY but it fell by 4.8% QoQ
The quick ratio has dropped by 53% year-on-year and by 8% since the previous quarter
The company's equity fell by 25% YoY and by 8% QoQ
Key stats
What are the main financial stats of ATOS
Market
Valuations
Earnings
Shares outstanding
125.8M
Market cap
$149.7M
Enterprise value
$74.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$26.91M
EBITDA
-$26.88M
Free cash flow
-$19.57M
Per share
Balance sheet
Liquidity
EPS
-$0.22
Free cash flow per share
-$0.16
Book value per share
$0.59
Revenue per share
$0
TBVPS
$0.63
Total assets
$79.48M
Total liabilities
$5.8M
Debt
$0
Equity
$73.68M
Working capital
$71.32M
Debt to equity
0
Current ratio
13.3
Quick ratio
12.92
Net debt/EBITDA
2.79
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-30.5%
Return on equity
-32.6%
Return on invested capital
-3,105.7%
Return on capital employed
-36.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATOS stock price
How has the Atossa Therapeutics stock price performed over time
Intraday
-0.83%
1 week
-13.14%
1 month
-17.93%
1 year
54.35%
YTD
35.23%
QTD
-21.71%
Financial performance
How have Atossa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.49M
Net income
-$26.91M
Gross margin
N/A
Net margin
N/A
The net income has grown by 10% YoY but it has contracted by 3.9% from the previous quarter
The operating income rose by 3.5% QoQ and by 3.3% YoY
Growth
What is Atossa Therapeutics's growth rate over time
Valuation
What is Atossa Therapeutics stock price valuation
P/E
N/A
P/B
2.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 8% YoY but it fell by 4.8% QoQ
The company's equity fell by 25% YoY and by 8% QoQ
ATOS's P/B is 8% above its 5-year quarterly average of 1.9 but 2.4% below its last 4 quarters average of 2.1
Efficiency
How efficient is Atossa Therapeutics business performance
ATOS's return on invested capital has dropped by 163% since the previous quarter
The return on equity has declined by 19% year-on-year and by 12% since the previous quarter
The ROA has decreased by 15% YoY and by 11% from the previous quarter
Dividends
What is ATOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATOS.
Financial health
How did Atossa Therapeutics financials performed over time
Atossa Therapeutics's total liabilities has surged by 68% YoY
Atossa Therapeutics's current ratio has plunged by 53% YoY and by 7% from the previous quarter
ATOS's debt is 100% smaller than its equity
The company's equity fell by 25% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.